Oral ibandronate in postmenopausal osteoporotic women alters micromechanical properties independently of changes in mineralization.
about
Long-term safety of antiresorptive treatment: bone material, matrix and mineralization aspectsOsteoporosis treatment: why ibandronic acid?Changes in the degree of mineralization with osteoporosis and its treatment.Material properties of bone in the femoral head treated with ibandronate and BMP-2 following ischemic osteonecrosis.Molecular alterations of bone quality in sequesters of bisphosphonates-related osteonecrosis of the jaws.
P2860
Oral ibandronate in postmenopausal osteoporotic women alters micromechanical properties independently of changes in mineralization.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Oral ibandronate in postmenopa ...... of changes in mineralization.
@en
Oral ibandronate in postmenopa ...... of changes in mineralization.
@nl
type
label
Oral ibandronate in postmenopa ...... of changes in mineralization.
@en
Oral ibandronate in postmenopa ...... of changes in mineralization.
@nl
prefLabel
Oral ibandronate in postmenopa ...... of changes in mineralization.
@en
Oral ibandronate in postmenopa ...... of changes in mineralization.
@nl
P2093
P2860
P1476
Oral ibandronate in postmenopa ...... of changes in mineralization.
@en
P2093
Georges Boivin
Joseph Kohles
Robert R Recker
Yohann Bala
P2860
P2888
P356
10.1007/S00223-012-9658-6
P407
P577
2012-10-23T00:00:00Z